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Abstract
Background: A somatic mutation in the FOXL2 gene is reported to be present in almost all (97%; 86/89) morphologically
defined, adult-type, granulosa-cell tumors (A-GCTs). This FOXL2 c.402C.G mutation changes a highly conserved cysteine
residue to a tryptophan (p.C134W). It was also found in a minority of other ovarian malignant stromal tumors, but not in
benign ovarian stromal tumors or unrelated ovarian tumors or breast cancers.
Methodology/Principal Findings: Herein we studied other cancers and cell lines for the presence of this mutation. We
screened DNA from 752 tumors of epithelial and mesenchymal origin and 28 ovarian cancer cell lines and 52 other cancer
cell lines of varied origin. We found the FOXL2 c.402C.G mutation in an unreported A-GCT case and the A-GCT-derived cell
line KGN. All other tumors and cell lines analyzed were mutation negative.
Conclusions/Significance: In addition to proving that the KGN cell line is a useful model to study A-GCTs, these data show
that the c.402C.G mutation in FOXL2 is not commonly found in a wide variety of other cancers and therefore it is likely
pathognomonic for A-GCTs and closely related tumors.
Citation: Schrader KA, Gorbatcheva B, Senz J, Heravi-Moussavi A, Melnyk N, et al. (2009) The Specificity of the FOXL2 c.402C.G Somatic Mutation: A Survey of
Solid Tumors. PLoS ONE 4(11): e7988. doi:10.1371/journal.pone.0007988
Editor: Anita Brandstaetter, Innsbruck Medical University, Austria
Received September 4, 2009; Accepted October 29, 2009; Published November 24, 2009
Copyright:  2009 Schrader et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by a grant from the Canadian Institutes of Health Research MOP 97735. CIHR had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript. The high resolution melt assay used to screen the solid tumors was internally funded and
performed at the Novartis Institutes for BioMedical Research. John Monahan and Bella Gorbatcheva of the Novartis Institutes for BioMedical Research designed
this portion of the study, collected and analysed the resulting data. The decision to publish and preparation of the manuscript was done in collaboration with
John Monahan and Bella Gorbatcheva.
Competing Interests: The British Columbia Cancer Agency is the holder of a provisional patent on the use of the FOXL2 mutation as a potential diagnostic and
therapeutic target. Bella Gorbatcheva and John Monahan are both employees of the Novartis Institutes for BioMedical Research. These competing interests do
not impact the sharing of data related to this publication.
* E-mail: dhuntsma@bccancer.bc.ca
. These authors contributed equally to this work.
Introduction
Malignant adult ovarian granulosa-cell tumors (A-GCTs) are
malignant sex cord-stromal tumors known for their genomic
stability and varied prognosis [1]. Until recently, there has been
little insight into the molecular characteristics of A-GCTs. Using
whole-transcriptome paired-end RNA sequencing, we identified a
somatic missense mutation (c.402C.G, p. Cys134Trp) in the
Forkhead transcription factor gene, FOXL2 [2]. This mutation was
present in 97% of 89 morphologically identified A-GCTs [2].
Foxl2 has been shown to be crucial for granulosa-cell differenti-
ation [3]. This was the first association of a somatic mutation in
FOXL2 associated with cancer, however aberrant expression of
Foxl2 has been reported in juvenile granulosa-cell tumor of the
testis [4]. The mutation was also found at a lower frequency in two
other related ovarian stromal tumors; 21% (3/14) thecomas and
10% (1/10) juvenile-type GCTs were mutation positive [2]. This
single, recurrent mutation suggests that it is characteristic of
granulosa-cell tumors, and its high frequency implies that it is
potentially a driver in disease initiation.
To determine the specificity of this somatic mutation, high
resolution melting or polymerase chain reaction (PCR) -based
allelic discrimination was used to screen a diverse collection of
tumors and ovarian tumor cell lines. Additional cytogenetic
analysis was performed to demonstrate the stable karyotype of the
A-GCT cell line, KGN [5].
Materials and Methods
Samples for the high resolution melt assay were purchased as
either DNA or tissue blocks from vendors who provided unlinked
anonymized specimens collected in accordance with applicable
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require an ethical review committee for samples collected in this
manner. Control DNA, used to validate the high resolution melt
assay, was extracted from anonymized tumor specimens compiled
by the frozen tumor bank, OvCaRe (Ovarian Cancer Research),
under written informed consent. Approval for analysis of these
samples for the FOXL2 mutation was obtained through the British
Columbia Cancer Agency’s research ethics board.
Seven hundred and fifty-two tumor DNA samples, of epithelial and
mesenchymal origin (Table 1) were screened with a high resolution
melting assay run on the LightScanner
TM instrument (Idaho
Technology Inc., Salt Lake City, Utah) [6,7]. For each tumor block,
malignant cells composed .50% of the cellularity and matched
normal adjacent tissue was available for all cases. The assay was
designed to detect sequence variants in the region from Ile102 to
Phe138 in Foxl2 (NP_075555.1). Since FOXL2 is a single exon gene,
PCR primers were placed in the coding region (forward primer 59
AGAAGGGCTGGCAAAATAGC, reverse primer 59 GCCG-
GTAGTTGCCCTTCT) resulting in a 150 base pair amplicon.
The primary screen used whole genome amplified (Qiagen
Repli-G kit) DNA derived from frozen tissue blocks of untreated
primary tumors. All samples which had an aberrant melting curve
or which failed to amplify in the initial screen were followed up
with a repeat HRM assay using unamplified DNA prepared from
tumor and adjacent normal tissue. Tumor samples which were
repeat positive for an aberrant melting curve were sequenced in
duplicate, and the resulting sequence trace files were analyzed for
mutations using the phrap/phred/consed software package (www.
phrap.org). DNA from 27 ovarian tumor samples previously
genotyped for the mutation using a previously validated TaqMan
real-time PCR-based allelic discrimination assay (Applied Biosys-
tems, Foster City, CA) specific for the FOXL2 c.402C.G mutation
[2] were used to validate the performance of the HRM assay. This
included an unreported A-GCT case and the cell line KGN.
To establish the specificity of the FOXL2 c.402C.G mutation
in ovarian cancer cell lines, we used the same TaqMan real-time
PCR-based allelic discrimination assay to genotype 28 ovarian
cancer cell lines and 52 cancer cell lines of different tissue origin
for the FOXL2 c.402C.G mutation (Table S1).
To assess the cytogenetic profile of KGN, we utilized 24-color
fluorescence in situ hybridization (FISH) (24XCyte, MetaSystems,
Cat. D-0125-120-MC) and analyzed the results using the Axioplan
2, Zeiss,(MetaSystems, Isis), camera VAC-30054.
Results
All 11 previously reported FOXL2 c.402C.Gm u t a t i o n -
p o s i t i v eA - G C Ts p e c i m e n sa sw e l la sa nu n r e p o r t e dA - G C T
Table 1. Summary of tumor types screened by High Resolution Melt Curve Analysis (HRM).
Total cases n=752
(excluding controls) Normal by HRM
Confirmed positive for FOXL2 c.402C.G
mutation out of HRM positive cases
Ovarian cancer negative controls 14 11 0/3*
Ovarian A-GCT positive controls (including an unreported
A-GCT case and the A-GCT cell line, KGN)
13 0 13/13
Bladder Cancer 40 40
Breast Cancer 74 71 0/3*
Carcinoid Cancer 8 8
Cervical Cancer 16 16
Colorectal Cancer 77 75 0/2*
Endometrial Cancer 12 12
Esophageal Cancer 21 21
Gastric Cancer 90 89 0/1*
Head & Neck Cancer 28 26 0/2*
Hepatic (HCC & Cholangiocarcinoma) 14 14
Lung Cancer (All types) 125 123 0/2*
Melanoma 31 31
Ovarian Cancer 32 32
Pancreatic Cancer 4 4
Prostate Cancer 37 37
Renal Cancer 52 51 0/1*
Leiomyosarcoma 15 15
Malignant fibrous histiocytoma-pleomorphic sarcoma 8 8
Rhabdomyosarcoma 2 2
Liposarcoma 4 4
Fibrosarcoma 1 1
Testicular Cancer 19 18 0/1*
Thyroid Cancer 42 42
Sequence data is available for all screen positive samples.
*Variants seen on HRM screen but not confirmed by sequencing (HRM false positive results).
doi:10.1371/journal.pone.0007988.t001
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demonstrating a variant melt curve distinct from the common
(wild-type) pattern. None of the 14 FOXL2 c.402C.Gm u t a t i o n
negative samples exhibited this v a r i a n tm e l tp r o f i l e .H o w e v e r ,
three of the 10 high grade serous ovarian cancers showed an
alternative variant profile; sequencing confirmed them to be false
positives.
The primary screen of 752 whole genome amplified tumor
DNA samples yielded 24 samples (,4%) with a variant profile,
distinct from that seen in association with the FOXL2 c.402C.G
mutation-positive A-GCT specimens, as well as 41 with an
indeterminate profile and 29 samples that failed. The secondary
screen was performed on this set of 94 samples using unamplified
genomic DNA derived from tumors and matching normal
specimens. Eighty-two of the samples were found to be false
positives where there was no variant profile seen between the
tumor and normal DNA. Twelve of the samples remained
indeterminate and were subsequently sequenced and confirmed
to be false positives.
The granulosa-cell line KGN, which was derived through long-
term passage of a recurrent A-GCT [5], was the only cell line
found to harbor the mutation. The mutation was not present in an
SVOG granulosa-cell line, immortalized by SV40 [8] or 26 other
ovarian cancer derived cell lines. Unlike most ovarian cancer
derived cell lines KGN shows relative genomic stability (Figure 1).
In addition to deletion of 7q, it is monosomic for chromosome
22 which is the most frequent cytogenetic abnormality seen in
A-GCTs [9]; another feature demonstrating its similarities to
A-GCTs.
Discussion
Loss-of-function germline mutations in FOXL2 are associated
with blepharophimosis–ptosis–epicanthus–inversus syndrome
[BPES;OMIM#110100]; an autosomal dominant developmental
disorder characterized by eyelid malformations and premature
ovarian failure due to a dysfunction of granulosa-cells [10]. The
FOXL2 c.402C.G mutation is seen in the heterozygous state in
most A-GCTs. Unlike in BPES, where germline FOXL2 mutations
are spread across the gene [11], the somatic FOXL2 mutation in A-
GCTs involves the same base pair in all cases. This favors a specific
functional consequence such as a dominant negative effect or a
change or gain of function as opposed to a generic loss of function
and the ultimate impact of this mutation is oncogenic. Additionally,
immunohistochemical data indicating that Foxl2 expression is
maintained in the nuclei in A-GCTs, that were heterozygous or
appeared to be hemizygous or homozygous for the mutation,
implies that this mutation does not affect protein localization [2].
Analysis of 28 various ovarian cancer-derived cell lines
demonstrated that the mutation was only present in the
granulosa-cell tumor cell line, KGN, suggesting that it is
molecularly akin to A-GCTs. The presence of the missense
mutation in the well-characterized A-GCT cell line, KGN, is in
keeping with the high frequency of the somatic mutation in A-
GCTs and supports the use of this cell model to study the
properties of this ovarian sex cord stromal tumor. This cell line has
been used in a number of elegant studies which have addressed the
question of the function of Foxl2 [12] and the effects of FOXL2
missense, haploinsufficient or hypomorphic mutations associated
Figure 1. Cytogenetic analysis of the KGN cell line. 24-color fluorescence in situ hybridization (FISH) demonstrates the tumor cell line’s stable
karyotype 45, XX, 7q-, -22 consistent with the original publication [5]. FOXL2 is located at 3q23. Images were obtained using the Axioplan 2, Zeiss,
(MetaSystems, Isis), camera VAC-30054.
doi:10.1371/journal.pone.0007988.g001
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attention to the possible confounding effects of this mutation in
one copy of the endogenous gene may elucidate the function of
this missense mutation in the granulosa-cell tumor.
The absence of the FOXL2 c.402C.G mutation in this large
series of common epithelial malignancies such as lung, colorectal,
breast, gastric, bladder, thyroid, prostate, melanoma and ovarian
carcinoma, in addition to a range of less frequent tumors, implies a
high specificity of this recurrent mutation for ovarian sex cord
stromal tumors. This study does not exclude the possibility that the
mutation could be found in other rare or related neoplasms such
as testicular stromal tumors. As the mutation was not found in
non-GCT ovarian tumor cell lines and the SV40 transformed
granulosa-cell line, SVOG, provides further support of its likely
role in A-GCT disease initiation. Considering the extremely high
frequency of this mutation in morphologically selected A-GCTs
(97%) [2], these data provide further evidence suggesting that the
mutation is also specific for this tumor type and could be useful as
a diagnostic test. Further studies will be required to determine the
relevance of the mutation in other sex cord stromal tumors of the
ovary, however, it is possible that all mutation positive tumors
could ultimately be considered to be a single entity of which the
major component would be A-GCTs.
Supporting Information
Table S1 Cell lines screened by TaqMan real-time PCR-based
allelic discrimination assay for the FOXL2 c. 402 C.G mutation.
Ovarian cancer cell lines are italicized and ovarian granulosa-cell-
derived lines are underlined.
Found at: doi:10.1371/journal.pone.0007988.s001 (0.02 MB
XLS)
Acknowledgments
We would like to thank the National Cancer Institute for providing us with
the NCI-60 cell line panel from the Division of Cancer Treatment and
Diagnosis (DCTD) Tumor Repository.
Author Contributions
Conceived and designed the experiments: KAS BG JDB CBG JM DH.
Performed the experiments: BG JS AHM NM CS SMB SLC JM.
Analyzed the data: KAS BG JS AHM NM PL JDB CBG JM DH.
Contributed reagents/materials/analysis tools: CS SMB SLC PL JDB
CBG JM. Wrote the paper: KAS BG JDB JM DH.
References
1. Koukourakis GV, Kouloulias VE, Koukourakis MJ, Zacharias GA,
Papadimitriou C, et al. (2008) Granulosa cell tumor of the ovary: Tumor
review. Integr Cancer Ther 7(3): 204–215.
2. Shah SP, Kobel M, Senz J, Morin RD, Clarke BA, et al. (2009) Mutation of
FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med.
3. Schmidt D, Ovitt CE, Anlag K, Fehsenfeld S, Gredsted L, et al. (2004) The
murine winged-helix transcription factor Foxl2 is required for granulosa cell
differentiation and ovary maintenance. Development 131(4): 933–942.
4. Kalfa N, Fellous M, Boizet-Bonhoure B, Patte C, Duvillard P, et al. (2008)
Aberrant expression of ovary determining gene FOXL2 in the testis and juvenile
granulosa cell tumor in children. J Urol 180(4 Suppl): 1810–1813.
5. Nishi Y, Yanase T, Mu Y, Oba K, Ichino I, et al. (2001) Establishment and
characterization of a steroidogenic human granulosa-like tumor cell line, KGN,
that expresses functional follicle-stimulating hormone receptor. Endocrinology
142(1): 437–445.
6. Reed GH, Wittwer CT (2004) Sensitivity and specificity of single-nucleotide
polymorphism scanning by high-resolution melting analysis. Clin Chem 50(10):
1748–1754.
7. Herrmann MG, Durtschi JD, Wittwer CT, Voelkerding KV (2007) Expanded
instrument comparison of amplicon DNA melting analysis for mutation
scanning and genotyping. Clin Chem 53(8): 1544–1548.
8. Lie BL, Leung E, Leung PC, Auersperg N (1996) Long-term growth and
steroidogenic potential of human granulosa-lutein cells immortalized with SV40
large T antigen. Mol Cell Endocrinol 120(2): 169–176.
9. Mayr D, Hirschmann A, Marlow S, Horvath C, Diebold J (2008) Analysis of
selected oncogenes (AKT1, FOS, BCL2L2, TGFbeta) on chromosome 14 in
granulosa cell tumors (GCTs): A comprehensive study on 30 GCTs combining
comparative genomic hybridization (CGH) and fluorescence-in situ-hybridiza-
tion (FISH). Pathol Res Pract 204(11): 823–830.
10. Crisponi L, Deiana M, Loi A, Chiappe F, Uda M, et al. (2001) The putative
forkhead transcription factor FOXL2 is mutated in blepharophimosis/ptosis/
epicanthus inversus syndrome. Nat Genet 27(2): 159–166.
11. Beysen D, De Jaegere S, Amor D, Bouchard P, Christin-Maitre S, et al. (2008)
Identification of 34 novel and 56 known FOXL2 mutations in patients with
Blepharophimosis syndrome. Hum Mutat 29(11): E205–19.
12. Batista F, Vaiman D, Dausset J, Fellous M, Veitia RA (2007) Potential targets of
FOXL2, a transcription factor involved in craniofacial and follicular
development, identified by transcriptomics. Proc Natl Acad Sci U S A 104(9):
3330–3335.
13. Benayoun BA, Batista F, Auer J, Dipietromaria A, L’Hote D, et al. (2009)
Positive and negative feedback regulates the transcription factor FOXL2 in
response to cell stress: Evidence for a regulatory imbalance induced by disease-
causing mutations. Hum Mol Genet 18(4): 632–644.
14. Beysen D, Moumne L, Veitia R, Peters H, Leroy BP, et al. (2008) Missense
mutations in the forkhead domain of FOXL2 lead to subcellular mislocalization,
protein aggregation and impaired transactivation. Hum Mol Genet 17(13):
2030–2038.
15. Moumne L, Dipietromaria A, Batista F, Kocer A, Fellous M, et al. (2008)
Differential aggregation and functional impairment induced by polyalanine
expansions in FOXL2, a transcription factor involved in cranio-facial and
ovarian development. Hum Mol Genet 17(7): 1010–1019.
Specificity of FOXL2 c.402C.G
PLoS ONE | www.plosone.org 4 November 2009 | Volume 4 | Issue 11 | e7988